Nektar Therapeutics

San Francisco, California, USA nektar.com

Overview

Nektar Therapeutics is a biopharmaceutical company developing a portfolio of drug candidates that leverage its PEGylation and polymer conjugate technology platforms. The company's research is focused on treatments for cancer, autoimmune disease, and chronic pain.

Therapeutic areas

OncologyImmunologyPain Management

API / Drug Master Files

Nektar Therapeutics holds 2 active (9 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

  • NKTR-255 DRUG PRODUCTActive2019-12-13
  • NKTR-255 DRUG SUBSTANCEActive2019-10-01
  • N-HYDROXYSUCCINIMIDYL ESTER OF BIS (METHOXYPOLY(ETHYLENE GLYCOL) MW 20,000) MODIFIED LYSINEInactive2010-05-07
  • AMIKACIN PULMONARY DELIVERY SYSTEMInactive2007-10-31
  • PEG2NHS40KPInactive2006-02-06
  • PEG2MAL40KInactive2006-01-27
  • METHOXYPOLY (ETHYLENE GLYCOL)- SUCCINIMIDYL BUTANOATE, MW 30,000 (MSBA30K)Inactive2001-08-06
  • METHOXYPOLY (ETHYLENE GLYCOL)- PROPIONALDEHYDE, MW 20, 000Inactive2000-11-10
  • METHOXYPOLY (ETHYLENE GLYCOL)- SUCCINIMIDYL CARBONATE, MW 12,000Inactive2000-06-02

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Nektar Therapeutics in our records. PharmaTek screens the full directory against live FDA enforcement data.

Related companies

454 Life Sciences Corporation
United States
Abbvie Inc.
United States
ABC Health Research Institute
USA
Abdera Therapeutics Inc.
United States
Abgenix, Inc.
United States
AC Biotech Incorporated
USA
Aclaris Therapeutics, Inc.
United States
Adcentrx Therapeutics, Inc.
United States

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.

Start free trialBook a demo